Titan focuses efforts on drug candidate for chronic pain

09/1/2008 | American City Business Journals

Titan Pharmaceuticals is concentrating on the development of Probuphine -- an experimental treatment for opioid addiction and chronic pain such as rheumatoid arthritis -- amid problems with two other drug candidates, President and CEO Dr. Marc Rubin said. The company plans to conduct more late-stage trials of Probuphine, which is delivered through a rod inserted under the skin, and seek FDA approval in 2010.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI